Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025)

Vaxcyte (PCVX) has reported Total Non-Current Liabilities for 7 consecutive years, with $317.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 54.39% year-over-year to $317.1 million; the TTM figure through Dec 2025 stood at $317.1 million (up 54.39% YoY), while the FY2025 annual figure was $317.1 million, up 54.39% from the prior year.
• Total Non-Current Liabilities grew to $317.1 million in Q4 2025 per PCVX's latest filing, from $205.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $317.1 million in Q4 2025 and bottomed at $40.2 million in Q4 2021.
• Historically, Total Non-Current Liabilities has averaged $92.4 million across 5 years, with a median of $54.0 million in 2021.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities declined 22.11% — and 2023, when it surged 218.61%.
• Vaxcyte's Total Non-Current Liabilities stood at $40.2 million in 2021, then jumped by 30.66% to $52.6 million in 2022, then soared by 218.61% to $167.4 million in 2023, then gained by 22.66% to $205.4 million in 2024, then soared by 54.39% to $317.1 million in 2025.
• Business Quant data shows PCVX's Total Non-Current Liabilities at $317.1 million in Q4 2025, $205.4 million in Q4 2024, and $167.4 million in Q4 2023.